ChinaDrugStatus

Pamiparib

帕米帕利
Brand: Partruvix / 百汇泽·Oncology·Last verified 2026-11-20

PARP inhibitor not renewed in the 2026 NRDL adjustment; explicitly granted a 6-month transition period under original payment terms through June 30, 2027.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Adjustment
Removed from 2026 NRDL (non-renewed negotiated drug)
Transition Clause
Original payment standard continues through Jun 30, 2027
Prior 2025 Listing
2025 NRDL #256 (Class B) — Restricted to patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after ≥2 prior lines of chemotherapy.

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-06-30)Transition Clause· Notice published: Nov 14, 2026

    6-Month Transition Period Ends

    Original negotiated payment standard remains reimbursable through June 30, 2027 per the 2026 NHSA notice.

    Chinese original: 未成功续约调出谈判药品给予6个月过渡期,2027年6月底前医保基金可按原支付标准继续支付。

  2. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Removed from Negotiated List

    Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027.

    Chinese original: 未成功续约调出2026版目录(原2025版谈判第256项);通知明确给予6个月过渡期,2027年6月30日前可按原支付标准继续支付。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

帕米帕利胶囊dosage name(NHSA)
BGB-290code(WHO)
百汇泽brand zh(NMPA)

Primary Sources for This Record